LAVAL, QC, Feb. 21 /PRNewswire-FirstCall/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the departure, effective February 21, 2008, of two members of its senior management team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President, Strategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice President, Business Development. The possibility of their acting as consultants in respect of specific projects is being explored.
"On behalf of the Board of Directors and my colleagues, I want to express our gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable contribution to Neurochem. We wish them every success in the future," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO.
Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute forward-looking statements. Such statements, based as they
are on the current expectations of management, inherently involve numerous
risks and uncertainties, known and unknown, many of which are beyond
Neurochem Inc.'s control. Such risks include but are not limited to: the
impact of general economic cond
|SOURCE NEUROCHEM INC.|
Copyright©2008 PR Newswire.
All rights reserved